Radioactive 'Tumor Seeker' drug enters human testing for multiple cancers
NCT ID NCT07261631
Summary
This is a first-in-human study testing a new radioactive drug designed to target and treat advanced solid tumors. The trial will enroll 180 adults with specific advanced cancers that have progressed after standard treatments. Researchers aim to find a safe and effective dose and see if the drug can help control tumor growth.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for COLORECTAL CANCER are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Novartis Investigative Site
RECRUITINGMontreal, Quebec, H3T 1E2, Canada
-
Novartis Investigative Site
RECRUITINGVandœuvre-lès-Nancy, 54511, France
-
Novartis Investigative Site
RECRUITINGHaifa, 3109601, Israel
-
Novartis Investigative Site
RECRUITINGTel Aviv, 6423906, Israel
-
Novartis Investigative Site
RECRUITINGSingapore, 168583, Singapore
Conditions
Explore the condition pages connected to this study.